The company has an internal once-weekly peptide (NNC-06620419, Phase 2 started October 2025), a ~$2B license on United Laboratories' UBT-251 (Phase 1b/2a running, 19.7% weight loss at 24 weeks in the Chinese Phase 2), a $2.2B collaboration with Septerna for small-molecule oral GPCR agonists including a triple, and a long-running in-house discovery pipeline
nov., a member of the phylum Bacteroidetes isolated from sediment of a eutrophic reservoir
They can reduce appetite, support weight loss, improve glucose control, and influence inflammatory pathways
IGF-1 availability is tightly regulated by the so-called insulin-like growth factor binding proteins (IGFBPs), which may act by increasing IGF-1 half-life, from minutes to hours (most commonly by forming a tertiary complex with Acid-Labile Subunit and IGFBP3), however blocking its binding to the insulin-like growth factor 1 receptor (IGF-1R) [9395]
[...] PSM applauds Arkansas Board of Pharmacy for protecting patients The Partnership for Safe Medicines applauds the Arkansas State Board of Pharmacy for utilizing new product verification technology for identifying illegitimate Ozempic quarantined by a pharmacy this week
Given numerous GLP-1RAs at various stages of development, future studies need not be limited to a single medication
